Kinney Horn Sells 1,092 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 1,092 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $25.00, for a total value of $27,300.00. Following the sale, the insider owned 1,092 shares in the company, valued at $27,300. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $23.35 on Friday. The business’s 50 day moving average price is $21.02 and its 200-day moving average price is $21.88. The firm has a market capitalization of $2.64 billion, a PE ratio of -9.81 and a beta of 2.07. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Hedge Funds Weigh In On Immunome

Several large investors have recently bought and sold shares of IMNM. KBC Group NV acquired a new stake in shares of Immunome in the 1st quarter valued at about $60,000. BNP Paribas Financial Markets increased its position in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the period. Strs Ohio acquired a new stake in Immunome during the 4th quarter worth approximately $64,000. Tower Research Capital LLC TRC grew its stake in shares of Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Immunome during the third quarter worth approximately $76,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on IMNM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research note on Thursday. Truist Financial lifted their price objective on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Leerink Partners lowered their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and an average target price of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.